(per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignancies Disease stabilization observed in patients with tumors harboring mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback